NRAS
About
Location: 1p13.2
Mappings
Biomarkers
NRAS is involved in the following curated biomarkers.
| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| Wild type NRAS | Wild type | 8 | 10 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab | |
| EMA (1) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab, Irinotecan | |
| EMA (1) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab, Fluorouracil, Oxaliplatin | |
| EMA (1) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Oxaliplatin, Panitumumab | |
| EMA (2) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Irinotecan, Panitumumab | |
| EMA (1) HSE (1) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Panitumumab | |
| HSE (1) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab, Fluorouracil, Irinotecan | |
| FDA (1) | HER2-positive, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Trastuzumab, Tucatinib |